SK bioscience CEO Jaeyong Ahn (left) and Doherty Institute director Professor Sharon Lewin at the signing ceremony. Credit: SK bioscience. SK bioscience and Australia’s Peter
NephroDI Therapeutics’ NDI-5001 is being developed to treat X-linked congenital nephrogenic diabetes insipidus, a rare genetic kidney condition. Credit: crystal light / Shutterstock.com. NephroDI Therapeutics
Erasca’s ERAS-801 will be used to treat malignant glioma, including glioblastoma. Credit: Nemes Laszlo / Shutterstock.com. Erasca has obtained orphan drug designation (ODD) from the
The combined company is expected to initiate three clinical trials of Tourmaline’s lead programme. Credit: Salov Evgeniy / Shutterstock.com. Talaris Therapeutics has entered a definitive
VASCEPA capsules are indicated for use in patients at increased risk of cardiovascular events caused by at least one other CV disease risk factor. Credit:
The Veeva CRM Suite and Veeva OpenData allow ADVANZ to coordinate more effectively with healthcare professional touchpoints across channels and regions. Credit: National Cancer Institute
The exterior panels on Ultragenyx’s new gene therapy manufacturing facility in Bedford, Massachusetts, are a representation of the sequenced human genome. Credit: Ultragenyx Pharmaceutical Inc.
LODOCO is indicated for reducing the risk of stroke, myocardial infarction and cardiovascular death in adult ASCVD patients. Credit: AGEPHA Pharma/ Business Wire. AGEPHA Pharma
The deal grants Coya Therapeutics exclusive patent rights and IP rights related to COYA 301 and combinations to treat Parkinson’s disease. Credit: Kateryna Kon via
The combination of Talzenna and Xtandi is indicated to treat metastatic castration-resistant prostate cancer in adult patients. Credit: MattL_Images via Shutterstock.com. The US Food and